Open Energy Market, Calculus portfolio company and a leading provider of energy procurement services and Net Zero technologies, has introduced a pioneering platform called True, which combines an organisation’s actual energy procurement costs with its Net Zero strategies.
Calculus has led an investment round into Laverock Therapeutics, a company developing a unique gene silencing platform for the creation of programmable advanced therapies.
Wonderhood Studios continue their stellar performance of signing household names as clients as part of their advertising business.
Maven Screen Media and Brouhaha continue progress.
Scancell achieve significant milestone for their cancer vaccine.
Calculus is delighted to launch the Calculus EIS Fund.
Arecor’s subsidiary Tetris Pharma have a signed an agreement with Goodlife.
Arecor to partner with a Top 10 Pharma to develop an enhanced antibody formulation for one of its investigational drugs.
Spectral MD has received certification to distribute and manufacture its DeepView wound imaging system.
Scancell’s phase I ModiFY trial assessing its cancer vaccine Modi-1 in various difficult-to-treat cancer types makes progress following a positive safety review.
Wonderhood commissioned for a new documentary on the Park Lane Hilton, further exhibiting its exciting slate.
Calculus Q2 2023 Quarterly Update showcasing some great news stories from our portfolio companies.
Arctic Shores are to work with some of the largest brewing brands on a new recruitment drive.
Its new documentary explores the legacy of famed music art studio Hipgnosis.
The new trial is designed to build on preliminary data supporting the notion that OBT-076 is able to deliver immune priming in chemo-refractory, advanced cancer patients.
The Annual General Meeting (AGM) of Calculus VCT plc will be held at 12pm on 21 of August 2023
Wonderhood’s latest production to premiere tells the tale of the British evacuation of Kabul in 2021 through military personnel’s experiences.
Arecor has a new level of protection for their proprietary insulin products in Europe and China.
Invizius continues to advance their work improving the lives of people requiring dialysis.
True, a platform designed to help business with their Net Zero strategy.
Brouhaha’s latest project impresses at prestigious Cannes Film Festival.
This encouraging research programme stems from a collaboration Destiny Pharma has with SporeGen Limited
The collaboration will see a new Phase 1b trial undertaken, investigating OBT’s lead asset, OBT076, in patients with Adenoid Cystic Carcinoma (ACC), a rare and aggressive type of cancer
The grant from the Medical Technology Enterprise Consortium (MTEC) will support the continued development of its fully portable handheld DeepView device